G
Description
Late-stage biopharmaceutical company (formerly Acasti Pharma) headquartered in Princeton, New Jersey, focused on rare and orphan diseases. Lead candidate GTx-104 (injectable nimodipine) is under FDA NDA review for aneurysmal subarachnoid hemorrhage.